PRICE HISTORY.
Use the left and right arrow keys to inspect dated observations. Home selects the first observation and End selects the latest.
Key numbers
Published fundamentals and the date each figure was recorded.
Anglo-French Drugs & Industries manufactures and markets pharmaceutical formulations, while also buying and selling pharmaceutical products as part of its healthcare operations. Its annual report identifies formulations across therapeutic groups including vitamins, sleep-inducing agents, anti-malarials, anti-epileptics, antibiotics, cardiac drugs, cold remedies, anti-ulcer products, hematinics, antifungals and oral hypoglycaemics. The company runs tablet, liquid, capsule and protein-preparation capabilities and carries out contract manufacturing for other companies. Its business is organised around divisions such as Optima, which sells medicines through Indian channels, and Hospicare, which serves orthopaedic and general-health needs through institutional and surgical channels. Revenue from operations in the audited statements is mainly product sales, with smaller operating revenue from scrap, job-work conversion charges and miscellaneous operating income. It also exports pharmaceutical products, with the report describing operations in multiple overseas markets.
About this company
Anglo-French Drugs & Industries Limited (AFDIL) is one of India's oldest pharmaceutical companies, with origins dating back to its incorporation in 1923. Headquartered in Bengaluru, Karnataka, the company has built a century-long presence in the Indian formulations market, developing and manufacturing a broad portfolio of nutraceutical and therapeutic products. The company operates through several focused divisions, commonly identified as AFD Pharma, Hospicare, Optima, along with dedicated trading and export functions. Its product range spans vitamins and protein food supplements, anti-epileptics, anti-oxidants, sleep-inducing agents, cold and cough preparations, digestive enzymes, calcium supplements, anti-malarials, antibiotics, cardiac and anti-inflammatory drugs. AFDIL markets several branded formulations across these segments and serves both domestic and international markets, with exports forming a part of its overall business. The business is associated with the Kanoria promoter family, with the board including Abhay Kanoria and Uddhav Abhay Kanoria among its directors. For the financial year ending March 2025, the company reported revenue in the region of ₹118 crore, supported by a relatively conservative balance sheet and a sizeable book value per share, reflecting its long operating history and accumulated reserves. Although the company carries a listed-type corporate identification number and its shares were historically admitted for dealing on the Metropolitan Stock Exchange of India (MSEI), the stock has not actively traded on that platform in recent years and the company is not listed on the NSE or BSE main board. As a result, its shares change hands in the off-market, where unlisted-share platforms quote an indicative price. AFDIL draws interest in the unlisted market because of its heritage brand, long-standing manufacturing footprint, steady revenue base in the health and nutrition space, and the limited free float available to investors seeking exposure to an established legacy pharmaceutical name outside the public exchanges. Figures shown here are indicative market data and may change with demand, supply, and company disclosures.
COMPANY REGISTRY · ON FILE
THE CREW · BOARD & MANAGEMENT
COMMON QUESTIONS.
Is Anglo French Drugs and Industries listed on the stock exchange?+
No. As of 2 September 2026, Anglo French Drugs and Industries is an unlisted company whose shares trade over-the-counter; it would list only if and when it completes an IPO.
What is the Anglo French Drugs and Industries unlisted share price?+
As of 2 September 2026, the indicative unlisted share price of Anglo French Drugs and Industries is ₹1,075 per share. This is an over-the-counter reference price, not a stock-exchange quote.
What indicative minimum amount is displayed for Anglo French Drugs and Industries unlisted shares?+
The displayed unit count is 10 share(s); at the indicative price of about ₹1,075, the displayed amount is approximately ₹10,750. This is a display convention, not evidence of inventory, an order minimum or a quote.
What is the ISIN of Anglo French Drugs and Industries?+
The recorded ISIN of Anglo French Drugs and Industries is INE570E01016. An ISIN is a 12-character security identifier. Verify it against the issuer and the relevant depository record before using it for any transfer or documentation.
Is trading in Anglo French Drugs and Industries unlisted shares legal in India?+
Unlisted shares can be transferred off-market in India, but the legal, tax and compliance position depends on the security, parties, documents and current rules. Verify the intermediary, issuer restrictions and applicable requirements before proceeding.
Is there a lock-in period for unlisted shares?+
A post-listing lock-in may apply under the rules in force at the time. The period and any exemptions can depend on the holder and acquisition, so check the current regulation and the issuer's offer documents rather than relying on a generic period.
Do you guarantee returns?+
No. Unlisted shares carry higher risk and lower liquidity than listed shares. Returns depend on company performance, market conditions and future listing outcomes. This is information only, not investment advice.